TY - JOUR AU - Anwar, Maheen AU - Aslam, Hafiz Muhammad AU - Anwar, Shahzad PY - 2015 DA - 2015/01/17 TI - PARP inhibitors JO - Hereditary Cancer in Clinical Practice SP - 4 VL - 13 IS - 1 AB - Poly (ADP-ribose) polymerases, abbreviated as PARPs, are a group of familiar proteins that play a central role in DNA repair employing the base excision repair (BER) pathway. There about 17 proteins in this family out of which the primary nuclear PARPs are PARP-1, PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a and -5b) .The PARP family members are known to engage in a wide range of cellular activities, for example, DNA repair, transcription, cellular signaling, cell cycle regulation and mitosis amongst others. The chief functional units of PARP-1 are an amino terminal DNA binding domain (DBD), a central auto modification domain (AMD), and a carboxyl-terminal catalytic domain (CD). PARP inhibitors are currently undergoing clinical trials as targeted treatment modalities of breast, uterine, colorectal and ovarian cancer. This review summarizes current insights into the mechanism of action of PARP inhibitors, its recent clinical trials, and potential next steps in the evaluation of this promising class of anti-cancer drugs. SN - 1897-4287 UR - https://doi.org/10.1186/s13053-014-0024-8 DO - 10.1186/s13053-014-0024-8 ID - Anwar2015 ER -